Respiratory delivered vaccines: Current status and perspectives in rational formulation design.
10.1016/j.apsb.2024.08.026
- Author:
Lan WU
1
;
Wenwen XU
1
;
Huiyang JIANG
1
;
Mingshi YANG
1
;
Dongmei CUN
1
Author Information
1. Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Publication Type:Review
- Keywords:
Biomacromolecule delivery systems;
Inhaled formulation;
Lung deposition;
Mucosal immunity;
Nucleic acid;
Particle engineering;
Respiratory drug delivery strategies;
Respiratory vaccines
- From:
Acta Pharmaceutica Sinica B
2024;14(12):5132-5160
- CountryChina
- Language:English
-
Abstract:
The respiratory tract is susceptible to various infections and can be affected by many serious diseases. Vaccination is one of the most promising ways that prevent infectious diseases and treatment of some diseases such as malignancy. Direct delivery of vaccines to the respiratory tract could mimic the natural process of infection and shorten the delivery path, therefore unique mucosal immunity at the first line might be induced and the efficiency of delivery can be high. Despite considerable attempts at the development of respiratory vaccines, the rational formulation design still warrants attention, i.e., how the formulation composition, particle properties, formulation type (liquid or solid), and devices would influence the immune outcome. This article reviews the recent advances in the formulation design and development of respiratory vaccines. The focus is on the state of the art of delivering antigenic compounds through the respiratory tract, overcoming the pulmonary bio-barriers, enhancing delivery efficiencies of respiratory vaccines as well as maintaining the stability of vaccines during storage and use. The choice of devices and the influence of deposition sites on vaccine efficiencies were also reviewed.
